Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cellectar Biosciences, Inc.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A serum HCV RNA level of \>100,000 IU/ml using a quantitative, branched-chain-DNA (bDNA)-based assay (lower limit of quantitation = \~650 IU/ml) or other equally sensitive quantitative methods.
Infection with genotype 1 HCV
Documented failure to respond to treatment (defined as a patient who did not achieve an early viral response (EVR) (≥2 log reduction in serum HCV RNA or undetectable HCV RNA after 12 weeks of treatment) OR is serum HCV RNA positive after 24 weeks of treatment with pegylated interferon plus ribavirin for hepatitis C
Adequate laboratory parameters
Women of childbearing potential willing to use two acceptable methods of birth control during trial participation or are sterile or post-menopausal (defined as not having a menstrual cycle for greater than two years)
Sexually active male subjects are practicing acceptable methods of contraception during trial participation
Have the ability to understand the requirements of the trial, have provided written informed consent, and agree to abide by the trial restrictions and to return for the required assessments
The subject must be able to self administer daily subcutaneous injections or their caregiver must be able to administer daily subcutaneous injections
You may not be if
Clinical, laboratory, or histological evidence of liver cirrhosis
Evidence of hepatic decompensation (presence of or a history of ascites, hepatic encephalopathy, variceal bleeding, or hepatocellular carcinoma)
Co-infection with human immunodeficiency virus (HIV) or active hepatitis B virus (HBV) (as determined by presence of hepatitis B surface antigen (HBsAg)
Have received pegylated interferon and/or ribavirin within the 60 days prior to enrollment
Any known preexisting medical condition that could interfere with the subject's participation in and completion of the protocol
Pregnant female or nursing mother
Clareo Health | A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
